TRANS GENIC INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 236 JPY | -1.26% |
|
-1.26% | -9.23% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.26TCr 8.1Cr 675.78Cr | Sales 2023 | 1.14TCr 7.36Cr 614.15Cr | Capitalization | 559.68Cr 3.6Cr 300.75Cr |
|---|---|---|---|---|---|
| Net income 2022 | 187.6Cr 1.21Cr 100.81Cr | Net income 2023 | -41Cr -26.33L -22Cr | EV / Sales 2022 | 0.35 x |
| Net cash position 2022 | 280.5Cr 1.81Cr 150.73Cr | Net cash position 2023 | 104.3Cr 67.14L 56Cr | EV / Sales 2023 | 0.4 x |
| P/E ratio 2022 |
3.89
x | P/E ratio 2023 |
-13.7
x | Employees | 236 |
| Yield 2022 |
0.71% | Yield 2023 |
0.9% | Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.26% | ||
| 1 week | -1.26% | ||
| Current month | -0.84% | ||
| 1 month | +2.16% | ||
| 3 months | +3.06% | ||
| 6 months | -8.17% | ||
| Current year | -9.23% |
1 week
233.00
242.00
1 month
222.00271.00
Current year
222.00271.00
1 year
222.00315.00
3 years
222.00655.00
5 years
222.00828.00
10 years
222.001 404.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kenji Fukunaga
CEO | Chief Executive Officer | 54 | 01/09/01 |
Kazuo Watanabe
DFI | Director of Finance/CFO | 56 | 01/17/01 |
| Director/Board Member | 64 | 01/11/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tsutomu Seito
BRD | Director/Board Member | 79 | 01/11/01 |
Kenji Fukunaga
CEO | Chief Executive Officer | 54 | 01/09/01 |
Yutaka Funabashi
BRD | Director/Board Member | 50 | 01/02/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/24/16 | 236 | -1.26% | 21 600 |
| 15/24/15 | 239 | -0.83% | 15,000 |
| 14/24/14 | 241 | 0.00% | 35,000 |
| 13/24/13 | 241 | +0.84% | 65,500 |
| 10/24/10 | 239 | +1.27% | 27,300 |
Delayed Quote Japan Exchange, May 16, 2024 at 11:30 am IST
More quotes
TRANS GENIC INC. is a Japan-based company mainly engaged in the biotechnology business. The Company has three business segments. The Contract Research Organization (CRO) segment is engaged in the provision of contract clinical tests for pharmaceuticals and foods, pharmacodynamic pharmacology tests, safety pharmacology tests, pharmacokinetic tests, and non-clinical tests such as safety tests for pesticides and food, the contract production of genetically modified mice and antibody, the sale of model mice, as well as the development of new biomarkers. The Diagnostic Analysis segment is engaged in the provision of pathological diagnosis services, gene analysis contract services, and drug discovery support services for individualized medicine. The TGBS segment is engaged in the provision of advice and support services for business succession and revitalization in various fields, as well as the electronic commerce (EC) business such as the retail and wholesale of electrical products.
Sector
Department Stores
Calendar
09/08/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.23% | 2.57Cr | |
| +21.37% | 1,93600Cr | |
| +42.96% | 4.03TCr | |
| +15.20% | 1.03TCr | |
| +11.31% | 866.44Cr | |
| -21.06% | 755.03Cr | |
| +12.76% | 668.38Cr | |
| -0.83% | 581.12Cr | |
| +7.47% | 547.76Cr | |
| -52.53% | 377.02Cr |
- Stock Market
- Equities
- 2342 Stock